Get the Stockscreener App
0.00
100.00%
-0.30
Altamira Therapeutics Ltd stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$0.30
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$1.13M
Revenue:
$132.70K
Net Income/Loss:
$-25.04M
P/E Ratio:
0.00
EPS:
-413.2312
Net Cash Flow:
-
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$2.4699
Altamira Therapeutics Ltd Stock (CYTO) Company Profile
Name
Altamira Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare CYTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTO
Altamira Therapeutics Ltd
|
0.00 | 1.13M | 132.70K | -25.04M | 0 | -413.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Altamira Therapeutics Ltd Stock (CYTO) Latest News
Press Release Distribution & PR Platform - ACCESS Newswire
Altamira Therapeutics to Host Full Year 2024 Financial Results and Business Update Call on April 30, 2025 - GlobeNewswire
Altamira Therapeutics to Host Full Year 2024 Financial Results and Business Update Call on - Bluefield Daily Telegraph
Altamira Therapeutics Secures Marketing & Distribution Agreements To Expand Sales Channels of Bentrio into Egypt and Pakistan - ACCESS Newswire
Altamira Therapeutics Reports 89.5% and 98.9% Reduction in Viral Load Against Human Rhinovirus With its Bentrio Nasal Spray - ACCESS Newswire
Altamira Therapeutics Announces Randomization of First Patient in Bentrio Trial in Seasonal Allergic Rhinitis - ACCESS Newswire
Altamira Therapeutics Amends Revenue Sharing Agreement with Altamira Medica - TipRanks
Altamira Announces Notice of Allowance from USPTO for Bentrio Nasal Spray Patent - GlobeNewswire
Altamira Therapeutics and Wellesta Expand Bentrio Marketing and Distribution Agreement to Include Two Additional Markets - ACCESS Newswire
Altamira Therapeutics to Provide Business Update on Bentrio(TM) Program - ACCESS Newswire
Altamira Therapeutics Receives Approval to Commence Clinical Trial Evaluating Bentrio in the Treatment of COVID-19 - ACCESS Newswire
In Vivo Data Presented at AHA Conference Demonstrates Altamira Therapeutics' SemaPhore mRNA Delivery Platform to Effectively Help Preserve Atherosclerotic Plaque Stability - ACCESS Newswire
Auris Medical and King's College London Extend Tinnitus Collaboration -February 22, 2017 at 08:02 am EST - Marketscreener.com
Altamira Reaches COVAMID Trial Enrollment Midpoint for Bentrio in Acute COVID-19 - ACCESS Newswire
Altamira Therapeutics Ltd. Announces Collaboration on Radiopharmaceutical Targeting Strategies - Marketscreener.com
Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies - GlobeNewswire
Liver Cirrhosis Clinical Trial Pipeline Experiences - GlobeNewswire
Altamira Therapeutics achieves nanoparticle-based delivery of circular mRNA - BioWorld Online
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA - The Manila Times
Altamira Therapeutics Ltd. Announces Successful Nanoparticle-Based Delivery of Circular RNA - Marketscreener.com
Nasdaq de-lists Altamira shares - Royal Gazette
Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets - Marketscreener.com
Altamira Therapeutics Moves to OTCQB After Nasdaq Delisting Over Minimum Bid Requirements - StockTitan
Altamira Therapeutics (NASDAQ:CYTO) Stock Price Down 1.3% – Here’s What Happened - Defense World
Loud and clear: Sound Pharma has phase III success in Meniere’s - BioWorld MedTech
CYTO stock plunges to 52-week low, touches $0.4 By Investing.com - Investing.com South Africa
ARMISTICE CAPITAL, LLC Acquires New Stake in Altamira Therapeuti - GuruFocus.com
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
Advancements in Sensorineural Hearing Loss Clinical Trial - GlobeNewswire
CYTO stock plunges to 52-week low, hitting $0.57 amid market challenges - Investing.com Australia
Here's Why Auris (CYTO) Is a Great 'Buy the Bottom' Stock Now - Nasdaq
Altamira Therapeutics Provides Update on Nasdaq Listing - GlobeNewswire
Altamira Medica obtains extended ISO 13485 certification By Investing.com - Investing.com UK
Altamira Therapeutics Announces Extended ISO 13485 Quality - GlobeNewswire
Nuance Pharma expands distribution of nasal spray Bentrio in East and South East Asia - BioSpectrum Asia
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results - GlobeNewswire
Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East Asia - The Manila Times
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024 - GlobeNewswire
Altamira Issues Pre-Funded Share Purchase Warrant - TipRanks
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering - GlobeNewswire
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia - GlobeNewswire
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11 - StockTitan
Altamira’s Bentrio nasal spray tests successfully - Royal Gazette | Bermuda
Bentrio nasal spray clears WADA substance test - Investing.com
Why Lumentum Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket - Benzinga
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models - GlobeNewswire
Altamira’s drug-delivering nanoparticles could treat AAA - Clinical Trials Arena
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles - GlobeNewswire
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management - Investing.com UK
Altamira Therapeutics Provides Business Update - GlobeNewswire
What's Going On With Altamira Therapeutics Stock? - Benzinga
Altamira Therapeutics Ltd Stock (CYTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):